CLINICAL_TRIALS
trial_result
· 2019-11-22
Clinical Trial Update: Effect of 120mg Somatuline Autogel at Different Dose Intervals (28, 42 or 56 Days) in Patients With Acromegaly [Phase 3]
Summary
A Phase 3 clinical trial evaluated 120 mg Somatuline Autogel given at 28, 42, or 56 day intervals in patients with acromegaly.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Ipsen | Conditions: Acromegaly | Phase 3 | Status: COMPLETED